Navigation Links
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
Date:2/10/2011

ted in the first half of calendar 2011. OSAG continues to recruit patients into a Phase IIb/III trial in pancreatic cancer patients. - YM's two randomized, Phase II, double-blind trials of nimotuzumab (for brain metastasis from non-small cell lung cancer and for palliative treatment of NSCLC) are lagging recruitment targets and consequently these programs are under review as the Company focuses support on the more advanced trials involving Daiichi Sankyo, which have the prospect of earlier registration trial initiation. YM's Phase II, second-line, single-arm study in children with progressive diffuse intrinsic pontine glioma (DIPG) has concluded recruitment at multiple sites in the US, Canada, and Israel and YM should report results in calendar Q1 2011.

CYT997:

- CYT997 is a small molecule therapeutic capable of being developed in IV and oral dose formulations with dual mechanisms of vascular disruption and cytotoxicity. Preliminary data from YM's current Phase I/II trial of CYT997 given IV in glioma patients are expected in calendar H2 2011.

Financial Results (CDN dollars)

Total revenue for the second quarter of fiscal 2011, ended December 31, 2010, was $0.3 million compared to $0.7 million for the second quarter of fiscal 2010, ended December 31, 2009. Total revenue for the first six months of fiscal 2011, ended December 31, 2010, was $0.7 million compared to $1.4 million for the first six months of fiscal 2010, ended December 31, 2010. Interest income for the first quarter of fiscal 2011 was $83 thousand compared with $13 thousand for the second quarter of fiscal 2010.

Licensing and product development expenses were $5.3 million for the second quarter of fiscal 2011 compared to $2.4 million for the second quarter of fiscal 2010. Licensing and product development expenses were $10.5 million for the first six months of fiscal 2011 compared to $4.8 million for the first six months of fiscal 2010. The increases were due mainl
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... Jan. 9, 2012 diaDexus, Inc. (OTC Bulletin ... vitro diagnostic products addressing unmet needs in cardiovascular ... approximately $4.9 million, up 48% from the prior ... 2011 revenue to $16.4 million, up 39% over ...
...   Sigma-Aldrich Corporation (NASDAQ: ... announced it has signed an agreement to acquire BioReliance Holdings, ... Avista Capital Partners for $350 million in cash.  The acquisition ... is expected to close in the first quarter of 2012.  ...
... 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ), ... of drugs for the treatment of human viral diseases, ... clinical trial of IDX184, the Company,s lead product candidate ... IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated ...
Cached Biology Technology:diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance 2diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 2Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 3Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 4Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 5
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... production of a protein called vasostatin may prove a promising ... of print in Gut. , Pancreatic cancer is the fifth ... is extremely difficult to treat. Only 3% of affected patients ... that has remained static for the past three decades. , ...
... scientists for the first time has detected a memory ... a single, new stimulus. The research, done with honeybees ... living brain and explore short-term memory as never before, ... on the report who is currently a postdoctoral research ...
... among American men. It is estimated ... six males will develop the disease during his lifetime. However, promising new ... One of the most innovative of these treatments is robotic-assisted laparoscopic prostatectomy ... one of only ...
Cached Biology News:Gene therapy potential for treatment of pancreatic cancer 2Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace 2Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace 3Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 3
...
...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
Biology Products: